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Background: Nonadherence is very common among subjects undergoing pharmacotherapy 
for schizophrenia and depression. This study aimed to evaluate the performance of the ratio of 
the nonlinear mixed effects pharmacokinetic model predicted concentration to observed drug 
concentration (ratio of population predicted to observed concentration (Cpred/Cobs) and ratio 
of individual predicted to observed concentration (Cipred/Cobs) as a measure of erratic drug 
exposure, driven primarily by variable execution of the dosage regimen and unknown true 
dosage history.
Methods: Modeling and simulation approaches in conjunction with dosage history information 
from the Medication Event Monitoring System (MEMS, provided by the “Depression: The search 
for treatment relevant phenotypes” study), was applied to evaluate the consistency of exposure 
via simulation studies with scenarios representing a long half-life drug (escitalopram). Adherence 
rates were calculated based on the percentage of the prescribed doses actually taken correctly 
during the treatment window of interest. The association between Cpred/Cobs, Cipred/Cobs 
ratio, and adherence rate was evaluated under various assumptions of known dosing history.
Results: Simulations for those scenarios representing a known dosing history were generated 
from historical MEMS data. Simulations of a long half-life drug exhibited a trend for overpre-
diction of concentrations in patients with a low percentage of doses taken and underprediction 
of concentrations in patients taking more than their prescribed number of doses. Overall, the 
ratios did not predict adherence well, except when the true adherence rates were extremely 
high (greater than 100% of prescribed doses) or extremely low (complete nonadherence). 
In general, the Cipred/Cobs ratio was a better predictor of adherence rate than the Cpred/Cobs 
ratio. Correct predictions of extreme (high, low) 7-day adherence rates using Cipred/Cobs were 
73.8% and 64.0%.
Conclusion: This simulation study demonstrated the limitations of the Cpred/obs and Cipred/obs 
ratios as metrics for actual dosage intake history, and identified that use of MEMS dosing   history 
monitoring combined with sparse pharmacokinetic sampling is a more reliable approach.
Keywords: adherence, Medication Event Monitoring System, dosing history, modeling and 
simulation
Introduction
Adherence to drug therapy is a largely undermeasured and underappreciated 
  phenomenon, which may possibly contribute to significant problems with response 
to therapy and toxicity. Nonadherence is very common among subjects receiving 
treatment for schizophrenia or depression, and potentially contributing to substantial 
variability in response.1–3 Researchers have demonstrated that poorly adherent subjects 
with schizophrenia had a higher risk of rehospitalization.1 In addition, the relationship Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of the time to first drug holiday with fluoxetine treatment 
and the probability of response among subjects with major 
depressive disorder were related.3 Therefore, measuring 
an individual’s specific dosage history condition is a very 
important piece of information in clinical trials, because 
the nonresponse or adverse drug effect may be caused by 
inconsistent drug intake.
The major measures of adherence include electronic mon-
itoring of a dosage form container (eg, the Medication Event 
Monitoring System [MEMS]4 caps, ie, the gold standard), 
pill count, patient interview/rating scales, pharmacokinetic 
indicators, and the evaluation of prescription refill records.5–8 
All of these methodologies are indirect approaches and have 
significant limitations.
A poor understanding of the adherence pattern that is 
most likely to contribute to a therapeutic problem3 represents 
a significant challenge in the area of pharmacotherapy. This 
issue is of particular importance in psychiatry where indi-
viduals with depression may be particularly susceptible to 
adherence patterns that relate to drug holidays as opposed 
to erratic, albeit consistent intake.3
Adherence can be conceptualized as the course of drug 
treatment and comprises three major components. These com-
prise acceptance of drug therapy (also referred to as initiation 
of drug therapy, ie, the patient starts taking the medication), 
execution of the prescribed drug regimen (ie, comparing the 
two time courses of drug intake, actual versus ideal), and 
discontinuation of the drug regimen (ie, the patient decides 
to stop taking the medication altogether). Acceptance and 
discontinuation are dichotomous, whereas execution is 
continuous. Persistence on drug therapy is defined as the 
time between acceptance and discontinuation.9 The method 
we propose for capturing erratic adherence patterns relates 
solely to the execution of the drug regimen.
Vrijens et al10,11 reported that using the detailed records 
of subjects’ dosing history not only helped to achieve 
convergence in model fitting under sparse sampling mea-
surement situations, but also explained 40% of residual 
variability in plasma lopinavir concentrations and reduced 
overall variability by 55%. Utilization of a prior established 
  pharmacokinetic/pharmacodynamic model may allow one to 
exploit this variability by evaluating the deviation between the 
prior model predicted and the observed drug concentrations 
at the population level (Cpred/Cobs), as well as the individual 
(Cipred/Cobs) level.
The primary objective of this study was to assess the stabil-
ity and robustness of the ratio of Cpred/Cobs and Cipred/Cobs 
in predicting adherence rates. This was accomplished using 
simulation approaches that incorporate design features of a 
typical psychiatric clinical trial (Depression: The search for 
treatment relevant phenotypes. see http://clinicaltrials.gov/ct/
show/NCT00073697)12 using the pharmacokinetic character-
istics of escitalopram as a representative long half-life drug. 
We hypothesize that the magnitude of the ratios of Cpred/
Cobs and/or Cipred/Cobs predict adherence (ie,   percentage 
of doses taken in a time window of interest).
Methods
Adherence definition and categorization
MEMS caps records from the study sponsored by the National 
Institute of Mental Health entitled “Depression: The search 
for treatment relevant phenotypes”12 were used to supply 
the “true” dosage histories. Determination of the adherence 
patterns used the MEMS patterns divided into two different 
observation windows (2 days and 7 days) immediately prior 
to the sampling time. The adherence “rate” was calculated 
from the dosage history obtained from MEMS caps into 
a proportion of dosages correctly taken over the window 
period of interest.
Specifically, adherence rate was equal to the total number 
of MEMS caps openings recorded divided by the number of 
doses prescribed. Adherence rates were categorized accord-
ing to total number of dosing events and frequency of drug 
administration (Table 1). The adherence rate was calculated 
for both 2-day and 7-day windows for each simulated clinic 
visit. This rate was used to classify adherence into   percentage 
categories.
Trial simulation
Observed concentrations were generated by the simulation of 
the virtual patients (ie, Cobs). The predicted concentrations 
were obtained using NONMEM estimation steps (the popula-
tion predicted and individual predicted represents the model 
predicted concentration at that sampling time based on the 
population prediction [Cpred] as well as the individual 
Table 1 Categorization of 7-day and 2-day adherence rate
Group 7-day history 2-day history
1 .100% .100%
2 85%–100% 50%–100%
3 30%–85% 0%–50%
4 0%–30% 0%
5 0% NA
Notes: Adherence rates were categorized given total number of dosing events 
and frequency of drug administration. Seven-day and 2-day history categories differ 
due to different numbers of dosage events possible in each time window allowing 
additional resolution in the 7-day history group.
Abbreviation: NA, not available.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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  prediction [Cipred]). A diagram depicting the simulation 
and estimation steps is shown in Figure 1.
Analysis platform
Nonlinear mixed effects modeling was employed for the 
population pharmacokinetic analysis as implemented in the 
NONMEM computer program (Version V , Icon Development 
Solutions, Elicott City, MD).13,14 The models consisted of a 
structural model that described the disposition of the drug fol-
lowing oral administration, and a pharmacostatistical model 
that described the residual interindividual and intraindividual 
variability. NONMEM was also utilized for performing 
the model-based simulations. “Virtual   subjects” datasets 
  simulation, graphics, and   postprocessing of   NONMEM 
outputs were performed using S-PLUS   (Version 6.2.1; 
Insightful, Seattle, WA). Perl (version.5.6) was   utilized as a 
scripting language to assist in automation of data   extraction 
and simulation routines.
Pharmacokinetic model for escitalopram
An established escitalopram model was utilized to represent 
the long half-life drug.15,16 A two-compartment model with 
additive and proportional residual error models was adapted 
from the literature reports for escitalopram as a long half-life 
drug (Table 2). The models were then used to generate a unique 
set of pharmacokinetic parameters for each patient using the 
UKNOWN DOSAGE HISTORY (UDH)  
Step 1: MEMS cap data – Generation of “virtual  
subject” dosing history 
Step 2: Simulation to generate pharmacokinetic profile using: 
 Known dosing history (MEMS)+ simulated pharmacokinetic
sampling time at each clinic visit (actual sampling time) and
pharmacokinetic model   
Step 3: Estimation of
pharmacokinetic profile under
known dosing history scenario
(MEMS + actual sampling time)
Step 4.2: Estimation of pharmacokinetic profile under
unknown dosing history scenario (nominal dosing + reported
sampling time)
Step 4.1: Simulation to generate pharmacokinetic profile
using: Unknown dosing history (assume 100% adherence +
simulated reported pharmacokinetic sampling time at each
clinic visit) and pharmacokinetic model
Step 5: Evaluation of simulation/estimation results
KNOWN DOSAGE HISTORY (KDH)   
Figure 1 Flow chart of simulation and estimation approach under known dosage history and unknown dosage history scenarios.
Abbreviation: MEMS, medication event monitoring system.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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NONMEM program (two-compartment, ADVAN4 TRANS4). 
In the model component, the individual parameter estimates are 
modeled as a function of typical values for the population and 
individual random deviations. The interindividual variability 
of the pharmacokinetic parameters is described below:
CL TVCL CL =× exp( ) η
where TVCL is the typical value of clearance for the popu-
lation, CL is the individual parameter estimate, and ηCL is 
the interindividual variability term on CL, representing the 
difference between the individual parameter estimate and the 
population mean. The inter-individual random variability are 
assumed to be log-normally distributed, with a mean of zero 
and variance of ω2.
Generation of Cobs, Cpred, and Cipred
A simulated (observed) plasma drug concentration (Cobs) was 
compared with model predicted concentrations using popula-
tion level (Cpred) and individual (Cipred) level parameter 
estimates. This was accomplished by fitting this simulated 
(observed) plasma drug concentration (Cobs) to generate the 
population and individual predicted   concentration values. 
This is shown in the equation below:
Cf x obs ij ij ii j [, ][ ,] [] [, ] ,, = () + θη ε
where Cobs[i, j] is the jth concentration measured in the ith 
subject, X[i, j] is the jth time in the ith subject, θ are the fixed 
effects parameters in the model, η[i] is the ith individual’s 
deviation in fixed effect from the population estimate and 
ε[i, j] is the residual error associated with the jth measured 
concentration in the ith individual. The Cpred[i. j] is evaluated at 
η[i] = 0 and Cipred[i. j] is evaluated at η[i] equal to the   maximum 
a posteriori Bayes estimate of the   individual   random 
effect (η[i]). Each simulated clinic visit was   associated with 
a single   concentration measurement.
Trial simulation and estimation
A flow chart of simulation and estimation steps is presented 
in Figure 1. Simulation scenarios for the virtual trials are 
summarized in detail (Table 3), including number of subjects, 
pharmacokinetic sampling per subject, simulation   replicates, 
etc. Figure one shows how the MEMS data (Step 1) were 
utilized as the actual dosing history (dose and time of 
dose taken) for subjects in the clinical trial “Depression: The 
search for treatment relevant phenotypes”.
Subjects recruited in the clinical trial had chronic psychi-
atric disorders. Dosing histories for the simulated trials were 
obtained by bootstrap resampling from the actual MEMS 
database in the phenotypes study.
Simulation (Step 2) was used to generate the “observed” 
concentrations (Cobs) for subjects at each clinic visit using 
the NONMEM simulation option.
Table 2 Pharmacokinetic parameters for a long half-life drug
Parameters Parameter estimates   
for long half-life drug
CL (L/h) 24.5
V2 (L) 417
Q (L/h) 35.7
V3 (L) 541
Ka (/h) 0.16
ωCL% 50
ωv2% 35
ωQ% 30
ωv3% 30
σ1% 30
Abbreviations: CL, clearance; V2, volume of distribution of central compartment; 
V3,  volume  of  distribution  of  peripheral  compartment;  Q,  intercompartment 
clearance; ω, coefficient of variation of interindividual variability; σ, coefficient of 
variation of residual error.
Table 3 Detailed description of simulation scenarios for a long 
half-life drug
Simulation profile  Simulation scenarios 
Sample size for each  
simulation replicate
65
Dose (mg) Long half-life drug (10)
Clinical visit record  
per subject (n)
18 (2–43 records)
Time of dose administration Actual: MEMS cap opening time
Nominal: 9 pm (normal distribution,  
SD = 1 hour)
Pharmacokinetic  
sampling time 
Actual: 8 am to 6 pm (uniform 
distribution)
Nominal: Actual sampling time + 
reported time error (normal distribution, 
SD = 15 minutes)
Adherence rate (%) Continuous adherence rate: 7-day and 
2-day actual rate
Categorical adherence: Adherence rate 
groups (very high, high, intermediate, low 
and extremely low) based on weekly and 
2-day pattern
Simulation replicates 100
Simulation conditions  MEMS data (number of doses taken)
Actual dosage time and actual 
pharmacokinetic sampling time
Estimation conditions  
for known dosage history
Dosing: MEMS dosing (number of doses 
taken)
Actual dosage time and actual sampling 
time
Estimation conditions for 
unknown dosing history
100% adherence rate (all doses taken)
Nominal dosage time and reported 
sampling time
Abbreviations: SD, standard deviation; MEMS, Medication Event Monitoring System.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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plots were generated for all the adherence rate categories. 
The box plot allows examination of the consistency of the 
Cpred/Cobs ratio in reflecting erratic adherence patterns 
(extremely low to high adherence). Under ideal conditions 
(known dosing history), the ratio of predicted and observed 
concentrations should be equal to one. Under the unknown 
dosing history scenario, concentrations were expected to be 
overpredicted if the adherence was less than 100% and under-
predicted if the actual adherence was over 100%. Thus, the 
systematic deviations of differences between the observed and 
the predicted concentrations could be reflected by the shift of 
the median ratio value with change of   adherence rate.
Rate classification using the established  
relationship between adherence rate and ratio
The central tendency of the ratio (mean) at each adher-
ence rate was calculated under unknown dosing history. 
  Exponential decay models were applied to characterize 
the relationship between Cpred/Cobs, Cipred/Cobs, and 
actual adherence rate for the 7-day and 2-day time win-
dows using NONMEM. The established relationships 
were then applied to predict adherence using the observed 
ratio. The ability to predict adherence correctly was used 
to evaluate the   performance of the relationship between 
ratio and   adherence rate.
The predicted adherence rate was classified based on min-
imum Euclidean distance classification criteria.17 At a given 
Cipred/Cobs ratio, the distance between the predicted rate 
and the observed rate was calculated using the equation:
d    =− AdherenceA dherence pred obs
The predicted adherence rate was assigned to the class 
(observed rate) for which the distance “d” was the minimum. 
The percentage of the correctly assigned rates was calculated 
for the 7-day and 2-day adherence periods.
Results
Subjects and MEMS data
MEMS data for a total of 65 patients were available from the 
ongoing depression phenotypes clinical trial during the first 
6 months, providing 863 clinic visit records. The adherence 
rate was calculated for each clinic visit event (pharmacoki-
netic sampling). These rates were then grouped into different 
time windows, eg, adherence rates 7 days prior to a clinic 
visit and 2 days prior to a clinic visit. The adherence rates 
were found to be highly variable within subjects during the 
treatment period. The 7-day adherence pattern had 9.7% 
Simulated datasets, comprising “virtual subjects” with 
unique virtual concentration time profiles (ie, the virtual 
Cobs values) were generated using the sampling conditions 
outlined in the phenotypes study as well as the residual 
unknown variability in the prior pharmacokinetic model. 
The actual pharmacokinetic sampling time at each clinic 
visit was simulated to occur between 8 am to 6 pm (clinic 
hours) using a pseudorandom uniform distribution. These 
simulated datasets provided individual pharmacokinetic 
parameters and concentration measurements (Cobs) for each 
virtual subject.
Simulation (Step 4.1) was also performed to create the 
subject with the incorrectly reported dosage history (nominal 
dose and dose-taking time) and the recorded pharmacokinetic 
sampling time. The erroneous nominal time of dose taken 
(incorrect dosing) was simulated from a normal distribution 
with a mean time of 9 pm, and a standard deviation (SD) of 
one hour. The reported pharmacokinetic sampling time was 
generated assuming a normal distribution using the actual 
time as the mean and a SD of 15 minutes. The pharmacoki-
netic samples were assumed to be taken at each clinic visit 
during regular clinic hours. An adherence rate of 100% was 
assumed for the unknown dosing history scenario.
Estimation (Step 3 and Step 4.2) was conducted under two 
conditions, ie, known dosage history, given the correct dos-
age history (MEMS cap data) and actual sampling time; and 
unknown dosage history, given incorrect (nominal) dosage 
history and reported (erroneous) sampling time. Population 
and individual pharmacokinetic parameters were estimated 
using NONMEM, and model predicted concentrations (Cpred 
and Cipred) were derived. The “observed” (ie, simulated from 
the virtual individuals as described in Step 2) concentrations 
were predicted based on individual-specific pharmacokinetic 
parameter estimates, and the Cpred/Cobs and Cipred/Cobs 
ratios were calculated in relation to the dosing history.
Due to the large number of simulation scenarios, the 
estimation of population and individual specific pharma-
cokinetic parameters, as well as the population predicted and 
individual Bayesian predicted concentrations, were obtained 
using the first-order method with the post hoc option in 
NONMEM.13
Evaluation of robustness of Cipred/Cobs: 
Cpred/Cobs for true adherence prediction
Ratios with true adherence rates  
for 2- and 7-day windows
The distribution of Cpred/Cobs and Cipred/Cobs ratios were 
evaluated across all adherence patterns. Box and Whisker Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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of the events with more than 7 doses taken (rate .100%), 
52.5% of events with 6–7 doses taken (rate 85%–100%), 
19.0% of events with 3–5 doses taken (rate 30%–85%), 4.3% 
of events with 1–2 doses taken (rate 0%–30%), and 14.5% 
with 0 doses taken (rate 0).
Simulation and estimation results
Box plots were generated for the long half-life drug under 
unknown dosing history and known dosage history scenarios 
(Figures 2 and 3). The known dosage history, where the 
estimation was based on the correct dosing history, had log 
median values of Cpred/Cobs and Cipred/Cobs ratios that 
were approximately zero at each adherence rate. This is 
shown in Figure 2A and 2B.
Under unknown dosing history scenario, the estima-
tion was based on the subjects’ incorrect dosage history. 
The median of the Cpred/Cobs and Cipred/Cobs ratios 
increased with decreasing adherence rate. This is shown in 
Figure 2C and 2D. The differences of the Cipred/Cobs ratio 
Figure 2 Box plot of the ratio distribution at each adherence rate condition for a long half-life drug. The box plots represent median (dots), 25th and 75 percentiles of the 
distribution. Notches show approximate 95% confidence limits for the median. A) Box-plot of the log Cpred:Cobs ratio under known dosage history. B) Box plot of the log 
Cipred:Cobs ratio under known dosage history. C) Box plot of the log Cpred:Cobs ratio under unknown dosage history. D) Box plot of the log Cipred:Cobs ratio under 
unknown dosage history.
Abbreviations: Cipred, individual predicted concentration; Cobs, observed concentration.
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across adherence rates appeared to be more substantial than 
that of Cpred/Cobs ratio under an unknown dosing history 
scenario.
Rate classification using modeled  
relationship between rate  
and adherence ratio
Relationship between 7-day adherence  
rate and ratio
The relationship between the median value of Cipred/Cobs 
ratio and the observed 7-day adherence rate was modeled. 
A biexponential function adequately described the relationship 
between Cipred/Cobs ratio and the weekly adherence rate. The 
observed adherence rate versus the Cipred/Cobs ratio, along 
with the Cipred from the unknown dosing history scenario, is 
shown in Figure 3. The exponential relationship between the 
Cipred/Cobs ratio and adherence rate is shown below:
Adherencee e
Cipred Cobs Cipred Cobs =+
−× −× 699 117
31 50 507 ./ ./Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
123
Measuring adherence to antidepressant therapy
Relationship between 2-day adherence rate and ratio
This same assessment was conducted for adherence rate 
categories arising for the 2-day period immediately prior to 
a clinic visit and concentration sampling. The relationship 
between this 2-day-based adherence rate and the Cipred/Cobs 
ratio was adequately described using a monoexponential 
function, as shown below:
Rate e
Cipred Cobs =
−× 834
20 5 ./
Similar relationships were found for the Cpred/Cobs ratio 
and adherence rate.
Performance of ratio as a measure  
of adherence rate
Rate classification for 7-day adherence rate
The exponential relationship developed above was applied for 
adherence rate prediction at each Cipred/Cobs ratio obtained 
under the unknown dosing history scenario, and then clas-
sified into the 7-day adherence category. The predicted rate 
classification was based on the minimum Euclidean distance 
classification criteria.17 The assigned rates were grouped 
based on weekly adherence patterns as described in the Meth-
ods section. The results of the correct rate classifications for 
each rate group are shown in Table 4. The result of the 7-day 
adherence rate conditions showed that the correct assigned 
rate in pharmacokinetic samples measured under the high 
adherence rate condition (ie, hypercompliant) was 73.8%. 
In pharmacokinetic samples measured under extremely 
low adherence rates (0% in the last week) the percentage 
of instances correctly classified was 64.0%. The rates were 
better classified in pharmacokinetic samples measured 
under extremely low (0%) and extremely high adherence 
rate conditions (.100%) than at intermediate adherence 
rate conditions.
Using Cipred/Cobs ratios to predict the 7-day adherence rate 
pattern, the overall rate of correct adherence classification was 
42.3%. The overall rate of correct adherence classification was 
26.4% when the Cpred/Cobs ratio was used as the predictor.
Rate classification for 2-day adherence rate
The adherence condition was well classified for the event 
under extremely high (rate . 100%) and extremely low 
(rate = 0%) adherence conditions. The correct classification 
rate (Table 5) was 80.8% for adherence .100%. The correct 
classification rate was 87.6% for adherence = 0%.
Using the Cipred/Cobs ratios to predict the 2-day adherence 
rate pattern, the overall rate of correct adherence classification 
was 50.2%. The overall rate of correct adherence classification 
was 29.9% using the Cpred/Cobs ratio as the predictor.
Discussion
It has been suggested that the inconsistency of drug exposure 
caused by variable adherence to prescribed therapy is the single 
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Figure 3 Association between Cipred:Cobs ratio and weekly adherence rate. Dots 
represented the median values of Cipred:Cobs ratio at each observed adherence 
rate condition. The line represented the model predicted weekly adherence rate at 
given Cipred:Cobs ratios. The vertical line represents a Cipred:Cobs ratio = 1 at a 
100% weekly adherence rate.
Abbreviations:  Cipred,  individual  predicted  concentration;  Cobs,  observed 
concentration.
Table 4 Correct classified 7-day adherence rate using Cipred: 
Cobs ratio as predictor
Adherence rate 
pattern 
Events (n) Correct 
classification (%)
Group 1  8014 73.82
Group 2 45319 39.19
Group 3 15972 36.65
Group 4 2733 25.72
Group 5 1128 64.01
Notes:  Group  1,  very  high  adherence  rate  condition  (.100%);  Group  2,  high 
adherence  rate  condition  (85%–100%);  Group  3,  intermediate  adherence  rate 
condition  (30%–85%);  Group  4,  low  adherence  rate  condition  (0%–30%);  and 
Group 5, extremely low adherence rate condition (0%).
Abbreviations:  Cipred,  individual  predicted  concentration;  Cobs,  observed 
concentration.
Table 5 Correct classified 2-day adherence rates using Cipred: 
Cobs ratio as predictor
Adherence rate 
pattern 
Events (n) Correct 
classification (%)
Group 1  8437 80.75
Group 2 43653 44.69
Group 3 17396 41.25
Group 4 3680 87.58
Notes: Group 1, extremely high adherence rate condition (.100%); Group 2, high 
adherence rate condition (100%); Group 3, intermediate adherence rate condition 
(50%); Group 4, extremely low adherence rate condition (0%).
Abbreviations:  Cipred,  individual  predicted  concentration;  Cobs,  observed 
concentration.Neuropsychiatric Disease and Treatment 2011:7 submit your manuscript | www.dovepress.com
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ways this one dose is actually taken. Therefore, the ratio 
metric and the 2-day adherence rate will have a stronger 
association than the association between the ratio and 7-day 
adherence rate.
Only 20% of the high, intermediate, and low adherence 
rates were correctly assigned. Therefore, electronic monitor-
ing, in addition to population pharmacokinetics, is necessary 
under these conditions, because these types of inconsistencies 
may still contribute adverse drug reactions, as well as treat-
ment resistance, and are not detectable using a Cipred/Cobs 
or Cpred/Cobs ratio approach. Thus, the single deviation 
observed using the population pharmacokinetic methodology 
has some serious limitations. The use of multiple observa-
tions (ie, as in the Brundage study)18 may be necessary to 
improve adherence classification or link these deviations to 
response. These results identified that use of MEMS dosing 
history monitoring in everyday clinical practice combined 
with sparse pharmacokinetic sampling could be a more 
  reliable approach.
The delayed effect between pharmacokinetic and phar-
macodynamic activity is common with central nerve system 
compounds, due to their mechanism of action in that most 
central nerve system compounds target neurotransmitters in 
the brain neuron synapse. The limitation of paper is that it 
only evaluated the impact of nonadherence on pharmacoki-
netics and the performance of Cipred/Cobs as a measure 
of erratic drug exposure, and the impact of erratic drug 
exposure on pharmacodynamics was not investigated in this 
simulation.
Conclusion
This simulation study demonstrated that the combination 
of the population pharmacokinetic model in the absence of 
robust adherence information from a source such as MEMS 
caps is limited as a method to detect erratic exposure with 
specific exceptions, eg, a subject has taken virtually no drug 
(extremely low adherence condition) or more drug than 
prescribed (the extremely high adherence condition). Both 
the extremely high and extremely low adherence rate condi-
tions are reasonably well predicted by the Cipred/Cobs and 
Cpred/Cobs ratio with a single observation. If the adherence 
patterns reflect an intermediate number of dosages taken, 
the single Cpred/Cobs or Cipred/Cobs measurement does 
not adequately reflect the adherence in this range. In this 
case, MEMS information in conjunction with population 
pharmacokinetics may be necessary. Therefore, this ratio 
may be helpful in identifying those who took virtually no 
drug or took more than the prescribed drug regimen.
largest source of variance in the drug response.11   Therefore, 
adherence plays an important role in   pharmacotherapy 
efficacy assessment, because the dosage adjustments may 
not be relevant if the subject is inconsistently receiving the 
prescribed medicine. The aim of this study was to identify 
erratic adherence using a modeling and simulation approach 
based on the possibility of taking a single concentration 
measure from a virtual patient and assessing whether or not 
this single measure provides an insight into how well the 
patient adhered with their medication regimen. This is the first 
study to evaluate the performance of the deviation between 
the population pharmacokinetic model predicted versus 
observed concentrations as an indicator of adherence rate for 
a target population. This was accomplished by developing a 
specific parametric relationship between the adherence rate 
calculated from MEMS data and the ratio of Cipred/Cobs and 
Cpred/Cobs as metrics reflecting these differences.
Seven-day and 2-day time windows were selected as two 
extreme conditions for adherence rate calculation. These 
windows were selected to link closely the information on 
dose taken with inconsistency of drug exposure. Our simu-
lation study suggested that the population pharmacokinetic 
modeling approach was most useful in the detection of 
extremely high and extremely low adherence rate patterns 
(Tables 4 and 5). These results are not unexpected, given 
that intermediate adherence rate patterns can arise from 
many different dosing histories, resulting in false assign-
ment based on the ratio. Consider the following example 
using the 2-day adherence rate pattern. Subject A has 
taken the dose on the first day of the 2-day time   window, 
subject B has taken the dose on the second day of the 2-day 
time window, and subject C takes all doses correctly in the 
2-day time window. Subjects A and B have a 50% adher-
ence rate, but their Cipred/Cobs ratios will be different. 
This explains how the Cpred/Cobs and Cipred/Cobs ratios 
predicts   adherence rates reasonably well only at the extremes 
(eg, 0% and .100% adherence).
The 2-day adherence rate patterns had a higher per-
centage of correct assignment than did 7-day adherence 
patterns (Tables 4 and 5). One explanation for this different 
  percentage of correct assignment is the result of different 
time windows used for adherence rate calculation, as dis-
cussed above. Specifically, for the 2-day adherence rate 
pattern, if the adherence rate is 50% (one dose taken in the 
2-day time window), there will be two combinations of how 
this one dose is actually taken, whereas for the 7-day adher-
ence rate pattern, if the adherence rate is 14% (one dose 
taken in the 7-day time window), there are seven possible Neuropsychiatric Disease and Treatment
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